ライフサイエンスコーパス: inhalation anthrax

1 nfective dose of 10(4)B. anthracis cells for inhalation anthrax.

2 ely devoid of virulence, in a mouse model of inhalation anthrax.

3 ternative clinical treatment regimen against inhalation anthrax.

4 the incubation period distribution for human inhalation anthrax.

5 that accurately predict the effects of human inhalation anthrax.

6 effective emergency therapy of postexposure inhalation anthrax.

7 racis may be critical in the early stages of inhalation anthrax.

8 AD is highly attenuated in a mouse model for inhalation anthrax.

9 0-4) for injection to 7 days (IQR, 4-9) for inhalation anthrax.

10 Inhalation anthrax, an often fatal infection, is initiat

11 lete solution for population protection from inhalation anthrax and has been associated with concerns

12 the onset of symptoms in all 6 survivors of inhalation anthrax and in 7 of 11 survivors of cutaneous

13 ients with bioterrorism-related cutaneous or inhalation anthrax and in a patient with laboratory-acqu

14 Since the initial events in inhalation anthrax are believed to be uptake of B. anthr

15 the protective activity of gammaDPGA Abs in inhalation anthrax are known.

16 gainst severe pathogenic infections, such as inhalation anthrax, are a critical need.

17 During advanced stages of inhalation anthrax, Bacillus anthracis accumulates at hi

18 F detection as a tool for early diagnosis of inhalation anthrax before the onset of fulminant systemi

19 cells were detectable in all 6 survivors of inhalation anthrax but in only 2 of 7 patients with cuta

20 hylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus

21 We show that protection against inhalation anthrax by an irradiated spore vaccine depend

22 toxin may play a role in the pathogenesis of inhalation anthrax by facilitating the dissemination of

23 Systemic sepsis, most often associated with inhalation anthrax, can cause massive ascites, electroly

24 % (CI, 96% to 100%), respectively, when only inhalation anthrax cases or higher-quality case reports

25 f-life confer significant protection against inhalation anthrax despite their lack of Fc regions.

26 Most patients with inhalation anthrax developed pleural effusions and more

27 otic that is used in combination therapy for inhalation anthrax disease.

28 amase-expressing bacteria) was evaluated for inhalation anthrax in cynomolgus macaques in 2 studies.

29 ated in a postexposure prophylactic model of inhalation anthrax in cynomolgus macaques.

30 LF, PA, and PGA levels during the course of inhalation anthrax in five rhesus macaques.

31 To better understand the pathogenesis of an inhalation anthrax infection, we propose a two-compartme

32 ategy for prophylaxis or treatment following inhalation anthrax infection.

33 Inhalation anthrax is a deadly disease for which there i

34 Successful postexposure treatment for inhalation anthrax is thought to include neutralization

35 xin genes and is capable of causing a severe inhalation anthrax-like illness.

36 conferred complete protection in the rabbit inhalation anthrax model.

37 us in the two most accepted animal models of inhalation anthrax, nonhuman primates and rabbits, but r

38 Prevention of inhalation anthrax requires early and extended antibioti

39 Inhalation anthrax results in high-grade bacteremia and

40 oxins in a New Zealand White rabbit model of inhalation anthrax; survival following a lethal aerosoli

41 the site of entry for Bacillus anthracis in inhalation anthrax, the deadliest form of the disease.

42 spore-laced letters resulted in 22 cases of inhalation anthrax, with five fatalities.

43 with 1 or more antimicrobials; patients with inhalation anthrax without meningitis fared better with

44 y appeared to be superior to monotherapy for inhalation anthrax without meningitis.

45 emination and lethality in a murine model of inhalation anthrax, yet the roles for the toxins during